WASHINGTON, Nov. 6 -- Lomond Therapeutics Holdings Inc. (NONE), Dover, Del., has filed a Form 4 with the Securities and Exchange Commission noting the change in the beneficial interest held by Director Carl L. Gordon, Dover.
On Nov. 1 the action involved acquisition of 2677256.0 common stock. Gordon now owns 1.1425309E7 common stock indirectly.
Disclaimer: Curated by HT Syndication....